From: Temporal trends in antimicrobial resistance of medically important pathogens on Curaçao
Model | Age | Female gender | Hospitalized versus GP | Outpatient versus GP |
---|---|---|---|---|
Amoxicillin/clavulanic acid | 1.004 (1.002–1.007)** | 0.720 (0.630–0.823)*** | 1.072 (0.932–1.233) | 1.289 (1.086–1.529)** |
Piperacillin/tazobactam | 1.005 (1.000–1.011) | 0.688 (0.536–0.887)** | 1.366 (1.036–1.810)* | 0.988 (0.686–1.410) |
Cefuroxime | 1.008 (1.004–1.012)*** | 0.544 (0.455–0.649)*** | 1.355 (1.107–1.662)** | 1.437 (1.129–1.827)** |
Ceftriaxone | 1.008 (1.003–1.013)** | 0.418 (0.335–0.522)*** | 1.648 (1.266–2.159)*** | 1.768 (1.299–2.407)*** |
Ceftazidime | 1.007 (1.001–1.012)* | 0.424 (0.338–0.531)*** | 1.676 (1.281–2.210)*** | 1.673 (1.216–2.302)** |
Gentamicin | 1.005 (1.001–1.010)* | 0.774 (0.637–0.942)* | 1.022 (0.822–1.273) | 1.593 (1.247–2.032)*** |
Trimethoprim | 1.000 (0.997–1.003) | 0.761 (0.661–0.876)*** | 1.154 (0.994–1.341) | 1.507 (1.260–1.802)*** |
Cotrimoxazole | 1.000 (0.997–1.003) | 0.737 (0.640–0.849)*** | 1.126 (0.967–1.312) | 1.504 (1.256–1.801)*** |
Ciprofloxacin | 1.013 (1.010–1.017)*** | 0.513 (0.444–0.594)*** | 0.921 (0.783–1.084) | 1.539 (1.276–1.857)*** |
Nitrofurantoin | 1.015 (1.005–1.027)** | 1.213 (0.737–2.082) | 1.343 (0.794–2.316) | 2.408 (1.361–4.287)** |
Fosfomycin | 1.011 (1.000–1.023) | 0.867 (0.533–1.432) | 1.166 (0.675–2.050) | 1.411 (0.740–2.655) |
MDOT | 1.011 (1.006–1.017)*** | 0.436 (0.354–0.536)*** | 1.014 (0.793–1.300) | 1.893 (1.453–2.469)*** |
Amoxicillin/clav. acid gentamicin | 1.014 (1.006–1.023)*** | 0.407 (0.295–0.559)*** | 1.299 (0.882–1.937) | 2.196 (1.452–3.348)*** |
Cefuroxime + gentamicin | 1.006 (1.001–1.010)* | 0.737 (0.602–0.904)** | 1.041 (0.829–1.310) | 1.556 (1.204–2.009)*** |
MRSA blood | 0.986 (0.972–0.999)* | 0.930 (0.502–1.695) | NA | NA |
MRSA soft tissue | 0.997 (0.990–1.003) | 0.952 (0.713–1.269) | 0.600 (0.409–0.890)** | 0.762 (0.497–1.176) |